Veracyte Appoints Muna Bhanji to Its Board of Directors
Veracyte, Inc. (Nasdaq: VCYT) has appointed Muna Bhanji, R.Ph., a seasoned healthcare executive, to its board of directors. With over 30 years in the biopharmaceutical field, Bhanji's expertise includes commercialization and market access strategies across global markets. CEO Bonnie Anderson expressed confidence in Bhanji's ability to support Veracyte's expansion, particularly with the upcoming international launch of the Envisia Genomic Classifier aimed at enhancing diagnostic capabilities for lung disease.
- Appointment of Muna Bhanji brings over 30 years of industry experience.
- Bhanji's background in commercialization could facilitate market expansion.
- Upcoming launch of Envisia Genomic Classifier may enhance diagnostic offerings.
- Potential challenges in integrating new board member into existing leadership structure.
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately.
Veracyte Appoints Muna Bhanji to Its Board of Directors (Photo: Business Wire)
“We are thrilled to welcome Muna Bhanji to our board,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “She is a healthcare industry veteran with a distinguished career of driving successful commercialization and market access strategies across a range of products in global markets. Her guidance will be instrumental as we expand our global footprint with a growing menu of advanced genomic tests that improve care for patients at every step of their journey. This includes our planned international introduction later this year of the Envisia Genomic Classifier on the nCounter Analysis System to improve diagnosis of patients with suspected interstitial lung disease.”
Ms. Bhanji brings more than 30 years of strategic and operational experience in the biopharmaceutical industry with a proven track record of commercial leadership, growth and value creation. She built her career at Merck, serving most recently as senior vice president of Global Market Access & Policy, Global Human Health. In that role, she developed pharmaceutical access and affordability strategies in a highly regulated environment, working with key stakeholders to support access to medicines in the United States, Europe, Japan, China and the emerging regions of Latin America, Asia Pacific, the Middle East and Africa. Ms. Bhanji serves on the boards of biopharmaceutical companies Ardelyx, Inc. and Cytokinetics, Inc., as well as the nonprofit organization Corus International. She previously served on the board of Possible Health, a non-profit with ties to Nepal that delivers affordable and high-quality care to rural and underserved communities. Ms. Bhanji also served on the board of the Foundation of Managed Care Pharmacy, which is the research, educational, and philanthropic arm of the Academy of Managed Care Pharmacy. Ms. Bhanji earned her Bachelor of Science in Pharmacy degree from Rutgers University and an M.B.A. from St. Joseph's University.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the planned expansion of our global footprint and menu of advanced genomic tests, including the planned international introduction of the Envisia Genomic Classifier on the nCounter Analysis System. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions Factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Veracyte’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, Envisia, and the Veracyte logo are registered trademarks of Veracyte in the U.S. and selected countries. Veracyte has common law rights and pending trademark applications for LymphMark and “More About You.”
nCounter is the registered trademark of NanoString Technologies, Inc. in the United States and other countries and used by Veracyte under license.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005174/en/
FAQ
Who is Muna Bhanji and what is her role at Veracyte?
What impact might Muna Bhanji's appointment have on Veracyte's business?
When is the international launch of the Envisia Genomic Classifier planned?
What is Veracyte's primary focus as a genomic diagnostics company?
